1. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med. 1994; 120:977–981.
2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990; 300:278–284.
Article
3. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997; 24:2–17.
4. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pep-tic-ulcer disease: a metaanalysis. Lancet. 2002; 359:14–22.
5. Kim JJ, Kim N, Lee BH, et al. Risk factors for development and recurrence of peptic ulcer disease. Korean J Gastroenterol. 2010; 56:220–228.
Article
6. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996; 110:1244–1252.
7. Dupas JL, Corallo J, Helberz T, Zaï m M. Acid suppression therapy is not required after one-week anti-Helicobacter pylori triple therapy for duodenal ulcer healing. Gastroenterol Clin Biol. 2000; 24:638–643.
8. Goh KL, Navaratnam P, Peh SC, et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. Eur J Gastroenterol Hepatol. 1996; 8:421–423.
9. Kim N, Lim SH, Lee KH, Jung HC, Song IS, Kim CY. Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. J Clin Gastroenterol. 1998; 27:321–326.
10. Hong SJ, Eun SH, Jung JS, et al. Longterm effect after Helicobacter pylori eradication in patients with peptic ulcer disease: A retrospective study. Korean J Med. 2002; 63:23–28.
11. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988; 2:12771280.
Article
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study Group. N Engl J Med. 2000; 343:1520–1528.
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888–1899.
Article
14. Cryer B, Feldman M. Effects of very low dose daily, longterm aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999; 117:17–25.
Article
15. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998; 338:727–734.